Effect of Q10 on the inflammatory factor interleukin-6 and TNF-alpha in radiopharmaceutical treatment.

Investigating the Effect of Q10 on Interleukin-6 (IL-6) factor and TNF-alpha in Iodine therapy patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240907062967N1

Enrollment

Registered

2024-10-03

Start date

2024-10-16

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer.

Interventions

Intervention 1: Intervention group: For patients who consume Q10, 300 mg of Q10 tablets were prescribed orally daily for 9 days. The procedure for starting the use of this tablet was before starting i

in other words, two different kits are used. The working principle of these kits is that the antigen required to measure the concentration of each cytokine is placed (coated) inside the wells of the 9

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age conditions between 18-60 years Willingness to participate in the study Absence of physical and genetic diseases Patients should undergo iodine therapy and the therapeutic dose of patients is between 100-150 mci. Patients suffering from thyroid cancer

Exclusion criteria

Exclusion criteria: Past history of acute and chronic physical, genetic disease, which leads to changes in the results Smoking and alcohol consumption Non-cooperation Having diabetes The person has been treated with radiotherapy or chemotherapy in the last year. Previous receipt of radioactive iodine and use of corticosteroid drugs

Design outcomes

Primary

Measure	Time frame
Levels of the inflammatory factor Tnf-alpha. Timepoint: The level of Tnf-alpha in 9 days after taking Q10 pills and not taking pills. Method of measurement: Using the ELISA method.;The level of inflammatory factor IL-6. Timepoint: At the beginning of the study (before starting iodine therapy) and at the end of the study (after 9 days in two control groups and the group that consumes Q10). Method of measurement: Using the ELISA kit.	—

Measure

Time frame

Levels of the inflammatory factor Tnf-alpha. Timepoint: The level of Tnf-alpha in 9 days after taking Q10 pills and not taking pills. Method of measurement: Using the ELISA method.;The level of inflammatory factor IL-6. Timepoint: At the beginning of the study (before starting iodine therapy) and at the end of the study (after 9 days in two control groups and the group that consumes Q10). Method of measurement: Using the ELISA kit.

—

Secondary

Measure	Time frame
Difference in the metabolism of patients. Timepoint: At the beginning of the study (before starting iodine treatment) and at the end of day 9 (in the control group and the group that consumes Q10). Method of measurement: The extent of changes in the inflammatory factors IL-6 and TNF-alpha by using the ELISA method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBensaeid Fatemeh

Shiraz University of Medical Sciences

fatemeh.bensaeid@gmail.com+98 61 5242 3676

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026